US FDA Approves Novo Nordisk's Ozempic to Cut Risk of Diabetic Kidney Disease Progression
(Reuters) -The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD), the Danish drugmaker said on Tuesday.
The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks ...
With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...
The safety committee of the European Medicines Agency (EMA) will again study the medication, semaglutide, out of concerns ...
Good news about an experimental weight-loss shot sent shares in Ozempic maker Novo Nordisk soaring, making it once again ...
We believe quality journalism should be available to everyone, paid for by those who can afford it. Popular weight loss drugs ...
Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback